Showing 6051-6060 of 7021 results for "".
- Chris Greta Appointed Chief Creative Officer at eRelevancehttps://practicaldermatology.com/news/chris-greta-appointed-chief-creative-officer-at-erelevance/2457996/Chris Greta has been appointed as the first chief creative officer for
- Philips Rolls Out New Three-In-One Skincare Devicehttps://practicaldermatology.com/news/philips-rolls-out-new-three-in-one-skincare-device/2457997/Philips is introducing Philips VisaPure Advanced, a new three-in-one facial skincare tool. The new device works to remove impurities that have accumulated in pores resulting in lesser appearance of enlarged or clogged pores and blackheads, which c
- Understanding How and When UV Rays Cause Melanomashttps://practicaldermatology.com/news/understanding-how-and-when-uv-rays-cause-melanomas/2458002/When melanocyte stem cells accumulate a sufficient number of genetic mutations, they can become the cells where melanomas originate, Cornell University researchers report. Under normal conditions, ultraviolet (UV) radiation from the sun activates melanocytes to release melanin, but if mel
- Study: Risk of Indoor Tanning Dependency Highest in Women with Depressive Symptomshttps://practicaldermatology.com/news/study-risk-of-indoor-tanning-dependency-highest-in-women-with-depressive-symptoms/2458003/More than one in five young, white women who have used indoor tanning at least once in the past year show signs of being addicted to the high dose of ultraviolet (UV) radiation from tanning beds. In addition, women with symptoms of depression were three times more likely to meet the crite
- Timing of Melanoma Diagnosis, Treatment Can Mean Life or Deathhttps://practicaldermatology.com/news/timing-of-melanoma-diagnosis-treatment-can-mean-life-or-death/2458004/The sooner melanoma patients are treated, the better their survival, particularly for stage I melanoma, according to a new study from the Cleveland Clinic. The research appears online today in the Journal of the
- Menlo Therapeutics Expands Management Teamhttps://practicaldermatology.com/news/menlo-therapeutics-expands-management-team/2458006/Menlo Therapeutics Inc., a late stage biopharmaceutical company, is developing a neurokinin 1 (NK‐1) receptor antagonist (serlopitant) for the treatment of pruritus associated with various underlying conditions, and for the treatment of refractory chronic cough. The company, which continues to ad
- FDA Clears Xstrahl Photoelectric Therapy Systemhttps://practicaldermatology.com/news/fda-clears-xstrahl-photoelectric-therapy-system/2458005/Xstrahl has received FDA 510K clearance for the marketing of its latest skin cancer therapy device. The Photoelectric Therapy System is a compact and ergonomic superficial X-Ray therapy system operating in the 10kV to 80kV range intended for superficial radiotherapy and surface electronic brachyt
- National Rosacea Society Awards New Grants; Call for 2018 Proposalshttps://practicaldermatology.com/news/national-rosacea-society-awards-new-grants/2458008/The National Rosacea Society (NRS) awarded funding for three new studies, in addition to continuing support for three ongoing studies, as part of its research grants program. Dr. Benjamin Kaffenberger, MD assistant professor of dermatology at the Ohio
- Ortho Dermatologics: Long-term Efficacy Data for Siliqhttps://practicaldermatology.com/news/ortho-dermatologics-long-term-efficacy-data-for-siliq/2458009/Siliq™ (brodalumab) injection provided sustained high levels of skin clearance (PASI 100) over more than two years in patients with moderate-to-severe psoriasis, according to data presented at the 2017 Fall Clinical Dermatology Conference in Las Vegas and reported by
- FDA Approves Stelara for Treatment of Adolescents with Moderate To Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-stelara-for-treatment-of-adolescents-with-moderate-to-severe-plaque-psoriasis/2458010/The FDA approved an expanded indication for Janssen Biotech, Inc.'s Stelara (ustekinumab) for the treatment of adolescents (12 years of age or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Today's approval marks a significant mile